Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére.

P. Andréka, Zoltán Nádházi, László Vándor, Eszter Takács, Gergely Szánthó, László Kónya, Z. Tulassay

Research output: Article

Abstract

Heart failure is characterized by sodium and fluid retention, sympathetic overactivation, parasympathetic withdrawal, vasoconstrictor activation and cytokine elevation. New therapies for heart failure attempt to control neurohormonal activation and limit progressive left ventricular dysfunction. Nesiritide (human B-type natriuretic peptide) is a recently approved new vasodilator that has been given to almost 1000 patients in numerous clinical investigations, it belongs to a new class of heart failure drugs known as natriuretic peptides. Nesiritide decreases pulmonary capillary wedge pressure, systemic vascular resistance, mean right atrial pressure and pulmonary artery pressure, while improving cardiac index, stroke volume and heart failure symptoms. Many endothelin receptor antagonists are in various stages of development. Early clinical studies have demonstrated beneficial cardiovascular hemodynamic effects. Other new drugs for heart failure also include calcium sensitizers, neutral endopeptidase and vasopeptidase inhibitors, aldosteron receptor antagonists, vasopressin antagonists and cytokine inhibitors. All are being actively investigated and many show significant promise as beneficial therapies in the treatment of heart failure.

Original languageHungarian
Pages (from-to)2053-2062
Number of pages10
JournalOrvosi Hetilap
Volume144
Issue number42
Publication statusPublished - okt. 19 2003

Fingerprint

Systolic Heart Failure
Heart Failure
Brain Natriuretic Peptide
Therapeutics
Cytokines
Neprilysin
Natriuretic Peptides
Pulmonary Wedge Pressure
Atrial Pressure
Left Ventricular Dysfunction
Vasoconstrictor Agents
Protease Inhibitors
Treatment Failure
Vasodilator Agents
Pharmaceutical Preparations
Vascular Resistance
Stroke Volume
Pulmonary Artery
Hemodynamics
Sodium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Andréka, P., Nádházi, Z., Vándor, L., Takács, E., Szánthó, G., Kónya, L., & Tulassay, Z. (2003). Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére. Orvosi Hetilap, 144(42), 2053-2062.

Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére. / Andréka, P.; Nádházi, Zoltán; Vándor, László; Takács, Eszter; Szánthó, Gergely; Kónya, László; Tulassay, Z.

In: Orvosi Hetilap, Vol. 144, No. 42, 19.10.2003, p. 2053-2062.

Research output: Article

Andréka, P, Nádházi, Z, Vándor, L, Takács, E, Szánthó, G, Kónya, L & Tulassay, Z 2003, 'Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére.', Orvosi Hetilap, vol. 144, no. 42, pp. 2053-2062.
Andréka P, Nádházi Z, Vándor L, Takács E, Szánthó G, Kónya L et al. Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére. Orvosi Hetilap. 2003 okt. 19;144(42):2053-2062.
Andréka, P. ; Nádházi, Zoltán ; Vándor, László ; Takács, Eszter ; Szánthó, Gergely ; Kónya, László ; Tulassay, Z. / Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 42. pp. 2053-2062.
@article{effe36e9c7d14949a6865d94d836ff12,
title = "Uj lehet{\'o}s{\'e}gek a systol{\'e}s sz{\'i}vel{\'e}gtelens{\'e}g gy{\'o}gyszeres kezel{\'e}s{\'e}re.",
abstract = "Heart failure is characterized by sodium and fluid retention, sympathetic overactivation, parasympathetic withdrawal, vasoconstrictor activation and cytokine elevation. New therapies for heart failure attempt to control neurohormonal activation and limit progressive left ventricular dysfunction. Nesiritide (human B-type natriuretic peptide) is a recently approved new vasodilator that has been given to almost 1000 patients in numerous clinical investigations, it belongs to a new class of heart failure drugs known as natriuretic peptides. Nesiritide decreases pulmonary capillary wedge pressure, systemic vascular resistance, mean right atrial pressure and pulmonary artery pressure, while improving cardiac index, stroke volume and heart failure symptoms. Many endothelin receptor antagonists are in various stages of development. Early clinical studies have demonstrated beneficial cardiovascular hemodynamic effects. Other new drugs for heart failure also include calcium sensitizers, neutral endopeptidase and vasopeptidase inhibitors, aldosteron receptor antagonists, vasopressin antagonists and cytokine inhibitors. All are being actively investigated and many show significant promise as beneficial therapies in the treatment of heart failure.",
author = "P. Andr{\'e}ka and Zolt{\'a}n N{\'a}dh{\'a}zi and L{\'a}szl{\'o} V{\'a}ndor and Eszter Tak{\'a}cs and Gergely Sz{\'a}nth{\'o} and L{\'a}szl{\'o} K{\'o}nya and Z. Tulassay",
year = "2003",
month = "10",
day = "19",
language = "Hungarian",
volume = "144",
pages = "2053--2062",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "42",

}

TY - JOUR

T1 - Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére.

AU - Andréka, P.

AU - Nádházi, Zoltán

AU - Vándor, László

AU - Takács, Eszter

AU - Szánthó, Gergely

AU - Kónya, László

AU - Tulassay, Z.

PY - 2003/10/19

Y1 - 2003/10/19

N2 - Heart failure is characterized by sodium and fluid retention, sympathetic overactivation, parasympathetic withdrawal, vasoconstrictor activation and cytokine elevation. New therapies for heart failure attempt to control neurohormonal activation and limit progressive left ventricular dysfunction. Nesiritide (human B-type natriuretic peptide) is a recently approved new vasodilator that has been given to almost 1000 patients in numerous clinical investigations, it belongs to a new class of heart failure drugs known as natriuretic peptides. Nesiritide decreases pulmonary capillary wedge pressure, systemic vascular resistance, mean right atrial pressure and pulmonary artery pressure, while improving cardiac index, stroke volume and heart failure symptoms. Many endothelin receptor antagonists are in various stages of development. Early clinical studies have demonstrated beneficial cardiovascular hemodynamic effects. Other new drugs for heart failure also include calcium sensitizers, neutral endopeptidase and vasopeptidase inhibitors, aldosteron receptor antagonists, vasopressin antagonists and cytokine inhibitors. All are being actively investigated and many show significant promise as beneficial therapies in the treatment of heart failure.

AB - Heart failure is characterized by sodium and fluid retention, sympathetic overactivation, parasympathetic withdrawal, vasoconstrictor activation and cytokine elevation. New therapies for heart failure attempt to control neurohormonal activation and limit progressive left ventricular dysfunction. Nesiritide (human B-type natriuretic peptide) is a recently approved new vasodilator that has been given to almost 1000 patients in numerous clinical investigations, it belongs to a new class of heart failure drugs known as natriuretic peptides. Nesiritide decreases pulmonary capillary wedge pressure, systemic vascular resistance, mean right atrial pressure and pulmonary artery pressure, while improving cardiac index, stroke volume and heart failure symptoms. Many endothelin receptor antagonists are in various stages of development. Early clinical studies have demonstrated beneficial cardiovascular hemodynamic effects. Other new drugs for heart failure also include calcium sensitizers, neutral endopeptidase and vasopeptidase inhibitors, aldosteron receptor antagonists, vasopressin antagonists and cytokine inhibitors. All are being actively investigated and many show significant promise as beneficial therapies in the treatment of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=1542500928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542500928&partnerID=8YFLogxK

M3 - Article

C2 - 14658417

AN - SCOPUS:1542500928

VL - 144

SP - 2053

EP - 2062

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 42

ER -